Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Similar immunogenicity of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine.

Van der Vliet D, Pepin S, Lambert M, Fauchoux N, Donazzolo Y, Dupuy M, Dakowski C, Denis M.

Hum Vaccin. 2010 Oct;6(10):823-8.

PMID:
20935517
2.

Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study.

Loebermann M, Anders G, Brestrich G, Fritzsche C, Klammt S, Boršo D, Frimmel S, Riebold D, Reisinger EC.

Vaccine. 2011 Feb 1;29(6):1228-34. doi: 10.1016/j.vaccine.2010.11.092.

PMID:
21167116
3.

Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.

Lu CY, Shao PL, Chang LY, Huang YC, Chiu CH, Hsieh YC, Lin TY, Huang LM.

Vaccine. 2010 Aug 16;28(36):5864-70. doi: 10.1016/j.vaccine.2010.06.059.

PMID:
20600484
4.

Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China.

Zhan Y, Yang Z, Li L, Ye D, Wu H, Fu R, Zhao S, Wang Y, Zhou R, Chen R.

Jpn J Infect Dis. 2011;64(3):190-4.

5.

Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.

Walker WT, Faust SN.

Expert Rev Vaccines. 2010 Dec;9(12):1385-98. doi: 10.1586/erv.10.141. Review.

PMID:
21105775
6.

Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011.

Girard MP, Katz JM, Pervikov Y, Hombach J, Tam JS.

Vaccine. 2011 Oct 13;29(44):7579-86. doi: 10.1016/j.vaccine.2011.08.031.

PMID:
21856358
7.

Immunogenicity and safety of pandemic H1N1 2009 vaccine among adults in field use, India.

Tandale BV, Pawar SD, Mishra AC.

Vaccine. 2012 Mar 9;30(12):2043-4. doi: 10.1016/j.vaccine.2011.10.008. No abstract available.

PMID:
22001279
8.

A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.

Roggelin L, Vinnemeier CD, Meyer S, Witte K, Marx L, Theeß W, Burchard GD, Rolling T, Cramer JP.

Hum Vaccin Immunother. 2015;11(10):2370-5. doi: 10.1080/21645515.2015.1064570.

9.
10.

Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.

Squarcione S, Sgricia S, Biasio LR, Perinetti E.

Vaccine. 2003 Mar 7;21(11-12):1268-74.

PMID:
12559808
11.

Immunogenicity and safety of a novel AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan.

Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Maeda A, Li P, Gillard P, Roman F.

Hum Vaccin. 2010 Nov;6(11):888-93.

PMID:
20980795
12.

Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.

Plennevaux E, Blatter M, Cornish MJ, Go K, Kirby D, Wali M, Reeves-Hoché MK, Denis M.

Vaccine. 2011 Feb 11;29(8):1569-75. doi: 10.1016/j.vaccine.2010.12.116.

PMID:
21219979
13.

[Study of reactogenicity, safety and immunogenicity of inactivated virosomal split influenza vaccine "Grifor" during phase I clinical trial].

Zverev VV, Korovkin SA, Mironov AN, Mel'nikov SIa, Mikhaĭlova NA, Kostinov MP, Dyldina NV, Zhirova SN.

Zh Mikrobiol Epidemiol Immunobiol. 2009 Jan-Feb;(1):26-31. Russian.

PMID:
19338233
14.
15.

Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.

Tremblay CL, Rouleau D, Fortin C, Toma E, Sylla M, Cyr L, Cote S, Baz M, Sampalis J, Trautman L, Sékaly RP, Boivin G.

Vaccine. 2011 Feb 4;29(7):1359-63. doi: 10.1016/j.vaccine.2010.12.023.

PMID:
21185423
16.

Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains.

Lee VJ, Tay JK, Chen MI, Phoon MC, Xie ML, Wu Y, Lee CX, Yap J, Sakharkar KR, Sakharkar MK, Lin RT, Cui L, Kelly PM, Leo YS, Tan YJ, Chow VT.

Vaccine. 2010 Oct 4;28(42):6852-7. doi: 10.1016/j.vaccine.2010.08.031.

PMID:
20723626
17.

Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.

Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, Leroux-Roels G.

Vaccine. 2008 Dec 2;26(51):6614-9. doi: 10.1016/j.vaccine.2008.09.078. Erratum in: Vaccine. 2010 Nov 23;28(50):8033.

PMID:
18930093
18.

Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea.

Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, Wie SH, Kim WJ.

Vaccine. 2011 Jan 10;29(3):523-7. doi: 10.1016/j.vaccine.2010.10.060.

PMID:
21055502
19.

Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety.

Madhi SA, Maskew M, Koen A, Kuwanda L, Besselaar TG, Naidoo D, Cohen C, Valette M, Cutland CL, Sanne I.

Clin Infect Dis. 2011 Jan 1;52(1):128-37. doi: 10.1093/cid/ciq004.

PMID:
21148531
20.

Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.

Vinnemeier CD, Fischer-Herr J, Meyer S, Liebig K, Theeß W, Burchard GD, Cramer JP.

Hum Vaccin Immunother. 2014;10(2):441-8. doi: 10.4161/hv.27140.

Items per page

Supplemental Content

Support Center